Shares are tanking today due to a missed goal in a mid-stage study. CNBC's Meg Tirrell reports. Also, home-grown Zika comes to the U.S. » Read More
U.S. FDA panel backs Valeant psoriasis drug with risk management. CNBC's Meg Tirrell reports.
United Therapeutics' Martine Rothblatt says investors with vision should get into her biotech firm now, before it grows to Google-like proportions.
Johnson & Johnson reported a 3.9 percent increase in second-quarter sales, helped by strength in its pharmaceuticals business.
Investors should skip buying Merck shares because of valuation and political risk, BMO Capital said.
The Chinese government is embarking on healthcare policy reform to improve accessibility and affordability, says Ally Bridge Group's Li Bin.
The latest MoneyTree report shows a rebound in venture capital investments, with the software industry leading in funding.
CNBC's Meg Tirrell reports the latest on Martin Shkreli's legal battle and the "Fast Money" traders weigh in on the biotech sector.
CNBC's Meg Tirrell reports on the trial set for former Turing Pharmaceuticals CEO Martin Shkreli.
The former Retrophin CEO is accused of looting the company to pay off hedge fund investors he was suspected of defrauding.
CNBC's Jim Cramer explains why he is watching Valeant Pharmaceuticals.
CNBC's Meg Tirrell speaks with Juno Therapeutics CEO Hans Bishop about the FDA's decision to take his company's immunotherapy trial off clinical hold.
The company's stock fell Wednesday amid news of a new short bet against Valeant's future and a big sale from its former CEO.
Shares of Teva rose more than 3 percent Wednesday morning after it increased its second-quarter profit and revenue guidance.
Check out the companies making headlines after the bell Tuesday.
The deaths had come in the company's "ROCKET" trial for patients with relapsed or refractory B cell acute lymphoblastic leukemia.
Jeff Jonas, Sage Therapeutics CEO, discusses a new way to treat postpartum depression. With CNBC's Meg Tirrell.
Shares of Shire rose more than 3 percent after it won approval from the FDA for its new dry-eye treatment Xiidra.
SAGE skyrockets after it announces results for a trial involving a drug to treat postpartum depression.
Jim Cramer explains why he is keeping an eye on shares of Sage Therapeutics.
Shares of Sagent Pharmaceuticals soared more than 39 percent after it agreed to be acquired by Nichi-Iko for $736 million.
Get the best of CNBC in your inbox